|
BioCryst Yanks IND on Hep Drug After FDA Safety Concerns
BioCryst Pharmaceuticals has decided to pull its IND for a new hepatitis C (HCV) drug after the FDA raised concerns about the drug’s toxicity profile.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives